Navigation Links
Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
Date:4/8/2013

CAMBRIDGE, Mass., April 8, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel therapy MM-121 restores tumor sensitivity and delays the onset of resistance to the aromatase inhibitor, letrozole, in an ER+ breast cancer model. The study was presented as part of the American Association for Cancer Research's 2013 Annual Meeting in Washington, DC, April 6-10, 2013.

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival. By inhibiting ErbB3 signaling, MM-121 was found to restore sensitivity, delay resistance and enhance the anti-tumor effect of letrozole as a combination therapy partner.

"In nearly all cases of advanced ER+ breast cancer, endocrine therapies are initially effective, but patients eventually develop resistance to these treatments," said Gavin MacBeath , Co-Founder and Head of Translational Research, Merrimack Pharmaceuticals. "We are excited to see that in preclinical models, MM-121 blocked activation of its target, ErbB3, and down-regulated several signaling pathways within these tumors.  We saw delayed resistance to letrozole when co-administered with the drug, and restored sensitivity when added after the tumors developed resistance to letrozole. These data help guide our thinking regarding how best to combine MM-121 with anti-hormonal therapies in the treatment of advanced ER+ breast cancer."

Study Methodology
The activity of MM-121 alone and in combination with letrozole was measured in an MCF7 in vivo model of post-menopausal ER+ breast cancer engineered to express aromatase. Models of ER+ breast cancer were randomized to receive letrozole, MM-121 or both MM-121 and letrozole following development of resistance to letrozole. Tumor
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
2. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
3. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
4. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
5. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
6. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
7. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
8. Valeant Pharmaceuticals Provides Update to Recent Event
9. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
10. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
11. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 ... has announced the addition of the  "2015 ... Market"  report to their offering.  ... comprehensive five-country report contains 500 pages, 120 ... suppliers and potential market entrants identify and ...
(Date:5/27/2015)... , May 27, 2015 Protein purification ... based on differences in their physical properties. The objective ... largest amount of functional protein with fewest contaminants. The ... grow at a CAGR of around 5% to 6% ... by increased research in the pharmaceutical and biotechnological fields, ...
(Date:5/27/2015)... DUBLIN , May 27, 2015 /PRNewswire/ ... ) has announced the addition of the  ... Trends And Forecasts (2014 - 2019)" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,Ultrasound is ... sound waves to look at body parts ...
Breaking Medicine Technology:European Hemostasis Diagnostic Testing Market Strategies 2015 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 3Asia Pacific Ultrasound Devices Market Report 2015 - Growth, Trends And Forecasts 2014 - 2019 2
... ANNAPOLIS, Md., April 13, 2011 PharmAthene, Inc. (NYSE ... has completed dosing in a U.S. Phase I clinical ... being developed for the prevention and treatment of inhalational ... clinical trial was designed to evaluate single escalating doses ...
... HONOLULU, April 13, 2011 Today, GE Healthcare announced ... the impact of DaTscan™ SPECT imaging on the clinical ... or symptoms of parkinsonian syndromes (PS). The results, presented ... an important step in documenting the value of DaTscan ...
Cached Medicine Technology:PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial 2PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial 3GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 2GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 3GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 4GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 5GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 6
(Date:5/27/2015)... 27, 2015 The BBB Code of ... practices that enhance customer trust and confidence in business. ... Trust, eight principles that summarize important elements of creating ... standards for business accreditation by BBB. Businesses based in ... and complete application procedures will be accredited by BBB. ...
(Date:5/27/2015)... May 27, 2015 With the launch ... more robust Network Management Module (NMM) tool, monitoring provider-network ... 21 issue of Atlantic Information Services, Inc.’s (AIS) Medicare ... NMM tool, as well as analysis from industry experts ... The changes coming to the NMM were announced at ...
(Date:5/27/2015)... Austin, TX (PRWEB) May 27, 2015 ... gas information. Topics include: Why investors should consider oil ... investors, how and why wells are drilled, industry news, ... , Carson Energy's 32 years of knowledge and experience ... and gas investment community to be able to access ...
(Date:5/27/2015)... May 27, 2015 The Case ... a partnership to provide CMSA's Career and Knowledge ... collaboration seeks to strengthen the case/care management workforce ... CKP program. The mutually beneficial agreement provides Medix, ... skills of talent in the healthcare, scientific and ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Coco Libre announced ... be able to reach for Organic Coconut Water to quench ... will be available at VIP areas, artist greenrooms, corporate skyboxes ... available at area hotels and on festival shuttle buses. ... this year,” said Noa Elan, Director of Strategic Partnerships for ...
Breaking Medicine News(10 mins):Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2
... New Zealand Aids Foundation has welcomed a decision by Pharmac(the ... the same time, they say delays over the funding may ... medicines, to be subsidized from April 1, 2007 are Tenofovir ... to Pharmac’s medical director Dr Peter Moodie the investment would ...
... slower in children who wear a special kind of ... lenses// according to a new study published in Investigative ... found that among children with two myopic parents, myopia ... when compared to those wearing single-vision lenses (SVLs).Knowing parental ...
... by a specialist headache centre, it was observed that eight ... at work; 91 per cent blamed the ineffectiveness to headaches, ... published in the March issue of Cephalalgia. ,"Migraines ... when they are often at their most productive, so the ...
... suggests that genes responsible for generating matrix metalloproteinase 1 ... long term hip replacement surgery. ,The researchers ... of whom (162) had problems after hip replacement in ... with symptoms, 91 had early signs of 'aseptic loosening,' ...
... SAN DIEGO--(BUSINESS WIRE)--Ichor Medical Systems, whose advanced electroporation ... effectiveness// of DNA drug and vaccine delivery, has ... $900,000 by the United States Department of Defense ... Institute of Infectious Diseases (USAMRIID) in Fort Detrick, ...
... certainly be an indicator of one’s happiness. Researchers at the ... nation's overall happiness and its citizens' blood pressure problems. ... across the European countries. ,These people were asked how happy ... blood pressure) and so on. ,While Sweden, Denmark ...
Cached Medicine News:Health News:New Zealand’s Pharmac Subsidies Two More HIV Drug 2Health News:Work Absence Due to Headaches Has a Substantial Socio-economic Effect 2Health News:United States Department of Defense Selects Ichor Medical Systems to Develop Biodefense Vaccine 2
Midstream Catch Kits...
... a portable, noninvasive ultrasound instrument that measures ... use, and quickly provides accurate results. In ... the BladderScan® to obtain a precise reading ... supplies the information that caregivers need to ...
... The BladderScan® BVI 6100 is a handheld, ... It is easy to operate, so any ... accurately. To view ultrasound images from exams ... patient records and reimbursement, just log on ...
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
Medicine Products: